Selective Multitargeted Drugs

Polypharmacology in Drug Discovery

Volumn , Issue , 2012, Pages 245-262

  Morphy, Richard ^a  

^a Schering Plough Newhouse   (United Kingdom)

Author keywords

MTDD, serendipity, drug discovery and DMLs; Screening and framework combination, lead generation; Selective multitargeted drugs

Indexed keywords

EID: 84886003093     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118098141.ch12     Document Type: Chapter

References (29)

1. Morphy, R.; Kay, C.; Rankovic, Z. (2004), From magic bullets to designed multiple ligands, Drug Discov. Today 9, 641-651.
2. Millan, M. J. (2006), Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application, Pharmacol. Ther. 110, 135-370.
3. Morphy, R.; Rankovic, Z. (2005), Designed multiple ligands. An emerging drug discovery paradigm, J. Med. Chem. 48, 6523-6543.
4. Kramer, M. S.; Last, B.; Getson, A.; Reines, S. A. (1997), The effects of selective D4 dopamine receptor antagonist (L-745, 870) in acutely psychotic inpatients with schizophrenia, Arch. Gen. Psychiatry 54, 567-572.
5. Shahid, M.;Walker, G. B.; Zorn, S. H.;Wong, E. (2009), Asenapine: A novel psychopharmacologic agent with a unique human receptor signature, J. Psychopharmacol. 23, 65-73.
6. Morphy, R. (2010), Selectively nonselective kinase inhibition: Striking the right balance, J. Med. Chem. 53, 1413-1437.
7. Stahl, S. M. (2002), Comparative efficacy between venlafaxine and SSRIs: A pooled analysis of patients with depression, Biol. Psychiatry 52, 1166-1174.
8. Bymaster, F. P.; Beedle, E. E.; Findlay, J.; Gallagher, P. T.; Krushinski, J. H.; Mitchell, S.; Robertson, D. W.; Thompson, D. C.; Wallace, L.; Wong, D. T. (2003), Duloxetine (Cymbalta TM), as dual inhibitor of serotonin and norepinephrine reuptake, Bioorg. Med. Chem. Lett. 13, 4477-4480.
9. Bamborough, P.; Drewry, D.; Harper, G.; Smith, G. K.; Schneider, K. (2008), Assessment of chemical coverage of kinome space and its implications for kinase drug discovery, J. Med. Chem. 51, 7898-7914.
10. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. (1997), Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Deliv. Rev. 23, 3-25.
11. Morphy, J. R. (2006), The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds, J. Med. Chem. 49, 2969-2978.
12. Morphy, J. R.; Rankovic, Z. (2006), The physicochemical challenges of designing multiple ligands, J. Med. Chem. 49, 4961-4970.
13. Morphy, R.; Rankovic, Z. (2007), Fragments, network biology and designing multiple ligands, Drug Discov. Today 12, 156-160.
14. Lowe, J.; Seeger, T.; Nagel, A.; Howard, H.; Seymour, P.; Heym, J.; Ewing, F.; Newman, M.; Schmidt, A. (1991), 1-Naphthylpiperazine derivatives as potential atypical antipsychotic agents, J. Med. Chem. 34, 1860-1866.
15. Howard, H.; Lowe, J.; Seeger, T.; Seymour, P.; Zorn, S.; Maloney, P.; Ewing, F.; Newman, M.; Schmidt, A.; Furman, J.; Robinson, G.; Jackson, E.; Johnson, C.; Morrone J. (1996), 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents, J. Med. Chem. 39, 143-148.
16. Garzya, V.; Forbes, I. T.; Gribble, A. D.; Hadley, M. S.; Lightfoot, A. P.; Payne, A. H.; Smith, A. B.; Douglas, S. E.; Cooper, D. G.; Stansfield, I. G.; Meeson, M.; Dodds, E. E.; Jones, D. N.; Wood, M.; Reavill, C.; Scorer, C. A.; Worby, A.; Riley, G.; Eddershaw, P.; Ioannou, C.; Donati, D.; Hagan, J. J.; Ratti, E. A. (2007), Studies towards the identification of a new generation of atypical antipsychotic agents, Bioorg. Med. Chem. Lett. 17, 400-405.
17. von Coburg, Y.; Kottke, T.; Weizel, L.; Ligneau, X.; Stark, H. (2009), Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics, Bioorg. Med. Chem. Lett. 19, 538-542.
18. Van Niel, M.; Beer, M.; Castro, J.; Cheng, S.; Evans, D.; Heald, A.; Hitzel, L.; Hunt, P.; Mortishire-Smith, R.; O'Connor, D.; Watt, A.; MacLeod, A. (1997), Parallel synthesis of 3-aryloxy-2-propanolamines and evaluation as dual affinity 5-HT1A and 5-HT re-uptake ligands, Bioorg. Med. Chem. Lett. 9, 3243-3248.
19. Ryckmans, T.; Balançon, L.; Berton, O.; Genicot, C.; Lamberty, Y.; Lallemand, B.; Pasau, P.; Pirlot, N.; Quéré L.; Talaga, P. (2002), First dual NK1 antagonists-serotonin reuptake inhibitors: Synthesis and SAR of a new class of potential antidepressants, Bioorg. Med. Chem. Lett. 12, 261-264.
20. Toda, N.; Tago, K.; Marumoto, S.; Takami, K.; Ori, M.; Yamada, N.; Koyama, K.; Naruto, S.; Abe, K.; Yamazaki, R.; Hara, T.; Aoyagi, A.; Abe, Y.; Kaneko, T.; Kogen, H. (2003), A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease, Bioorg. Med. Chem. 11, 4389-4415.
21. Sterling, J.; Herzig,Y.; Goren,T.; Finkelstein, N.; Lerner, D.; Goldenberg,W.; Miskolczi, I.; Molnar, S.; Rantal, F.; Tamas, T.; Toth, G.; Zagyva, A.; Zekany, A.; Lavian, G.; Gross, A.; Friedman, R.; Razin, M.; Huang, W.; Krais, B.; Chorev, M.; Youdim, M. B.; Weinstock, M. (2002), Novel dual inhibitors of AchE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease, J. Med. Chem. 45, 5260-5270.
22. Sagi, Y.; Drigues, N.; Youdim, M. B. (2005), The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats, Br. J. Pharmacol. 146, 543-552.
23. Chen, J. F.; Steyn, S.; Staal, R.; Petzer, J. P.; Xu, K.; Van Der Schyf, C. J.; Castagnoli, K.; Sonsalla, P. K.; Castagnoli, N., Jr.; Schwarzschild, M. A. (2002), 8-(3-Chlorostyryl) caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism, J. Biol. Chem. 27, 36040-36044.
24. Piazzi, L.; Cavalli, A.; Colizzi, F.; Belluti, F.; Bartolini, M.; Mancini, F.; Recanatini, M.; Andrisano, V.; Rampa, A. (2008), Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds, Bioorg. Med. Chem. Lett. 18, 423-426.
25. Gengo, P. J.; Pettit, H. O.; O'Neill, S. J.;Wei, K.; McNutt, R.; Bishop, M. J.; Chang, K.-J. (2003), DPI-3290 [(+)-3-((alpha-R)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)- 3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. Mixed opioid agonist with potent antinociceptive activity, J. Pharmacol. Exp. Ther. 307, 1221-1226.
26. Ananthan, S.;Kezar,H. S., III; Carter, R. L.; Saini, S. K.; Rice, K. C.;Wells, J. L.; Davis, P.; Xu, H.; Dersch, C. M.; Bilsky, E. J.; Porreca, F.; Rothman, R. B. (1999), Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido-and pyrimidomorphinans, J. Med. Chem. 42, 3527-3538.
27. Dardonville, C.; Jagerovic, N.; Callado, L.; Meana, J. (2004), Fentanyl derivatives bearing aliphatic alkaneguanidinium moieties: A new series of hybrid molecules with significant binding affinity for μ-opioid receptors and I2-imidazoline binding sites, BMC Clin. Pharmacol. 5(1), 3.
28. Portoghese, P. S. (2001), From models to molecules: Opioid receptor dimers, bivalent ligands, and selective opioid receptor probes, J. Med. Chem. 44, 2259-2269.
29. Daniels, D. J.; Kulkarni, A.; Xie, Z.; Bhushan, R. G.; Portoghese, P. S. (2005), A bivalent ligand (KDAN-18) containing δ-antagonist and κ-agonist pharmacophores bridges δ2 and κ1 opioid receptor phenotypes, J. Med. Chem. 48, 1713-1716.